DiscoverResearch To Practice | Oncology VideosHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

Update: 2025-11-20
Share

Description

Featuring an interview with Dr Erika Hamilton, including the following topics:

  • General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00 )
  • Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11 )
  • Mechanisms of resistance to endocrine therapy (10:08 )
  • Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26 )
  • Other applications for PROTACs (24:24 )
  • Emerging data from the Phase III evERA trial (27:38 )
  • Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51 )

CME information and select publications

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

Dr. Neil Love